crowdfunding

Online Angel Funding Model Greenlighted by SEC?

While rulemaking to implement the equity crowdfunding mandates of the JOBS Act remains in limbo awaiting the seating of a new SEC chair, the agency moved last week to approve an online angel funding group’s compensation model that would be exempt from some of the JOBS Act’s more costly and vexing requirements for crowdfunding platforms. The approval of FundersClub’s “carried interest” model  paves the way for angel platforms to begin raising funds from accredited crowd investors immediately. In a No-Action letter published last week the SEC said that FundersClub’s proposed compensation model, which relies solely on carried interest in its funded companies, qualified for the angel platform exemption from registration, general solicitation and broker-dealer requirements for Title II and III equity crowdfunding platforms in the JOBS Act’s Section 201(c). The SEC’s move is significant because it allows online funding platforms that restrict their investors to bona fide accredited investors and only take compensation from the investment gains of stakes held in the platform’s portfolio companies to begin fundraising immediately without further rulemaking from the agency. The rulemaking to implement Title II-style equity crowdfunding has been stalled for seven months after the SEC released a proposed rule addressing the mandated repeal of the general solicitation rule for restricted securities which was widely criticized as opening the flood gates to fraud. Former SEC chair Mary Shapiro left the agency in December without finalizing the repeal of the solicitation rule, reportedly fearing a repeal would ruin her legacy as a securities regulator.

VC

Late Stage VC Rounds Start Year with Bang

While fiscal cliff fears and free-floating economic gloom dampened the final weeks of 2012, venture investors interested in up-and-coming companies have been busy in the first weeks of 2013. Companies that saw post-start-up VC investors coming back for more include Versartis, Streetline, Pontiflex, Panaya, LED Engin, Pure Storage, BuzzFeed and Aileron Therapeutics. Versartis, a Redwood City, Calif.-based growth hormone developer, closed a $25 million Series C round. The company is currently enrolling children for a study of VRS-317, a long-acting growth hormone for the treatment of pediatric growth hormone deficiency. Versartis is in clinical trials with both adult and pediatric versions of the hormone.

VC

Late Stage Investors Bring the Bucks to Likes of Kabam, Coveo

With IPO markets lolling in a post-Facebook (FB) malaise, public offerings are not an easy way to raise capital. Yet late-stage venture investing continues to provide growing, robust companies with substantial infusions of cash. Companies currently enjoying late stage rounds include 23andMe, Coveo, Kabam and One Kings Lane. Personal genetics specialist 23andMe is on the receiving end of $50 million in a Series D round with Investors including Yuri Milner of Digital Sky Technologies fame. DST has lead substantial investments in the likes of Facebook, Zynga (ZNGA), Groupon (GRPN) and Chinese web mall 360buy.com.